Institution
Victor Chang Cardiac Research Institute
Nonprofit•Sydney, New South Wales, Australia•
About: Victor Chang Cardiac Research Institute is a nonprofit organization based out in Sydney, New South Wales, Australia. It is known for research contribution in the topics: Mechanosensitive channels & Heart failure. The organization has 708 authors who have published 1599 publications receiving 70035 citations.
Papers published on a yearly basis
Papers
More filters
••
[...]
TL;DR: Helical regions formed from putative π-helices actually consist of a series of concatenated wide turns with unique elliptical configurations, which obviates the helical void and endows proteins with important functionalities, including metal ion coordination, enhanced flexibility and specific enzyme-substrate binding interactions.
29 citations
••
TL;DR: This study defines the microenvironment required to achieve a reproducible in vitro model of beating, myogenic cell clusters and identifies c‐kitpos bone marrow hematopoietic cells as the source of the myogenic clusters.
Abstract: In recent years, the differentiation of bone marrow cells (BMCs) into myocytes has been extensively investigated, but the findings remain inconclusive. The purpose of this study was to determine the conditions necessary to induce myogenic differentiation in short-term cultures of adult BMCs, and to identify the BMC subpopulation responsible for this phenomenon. We report that high-density cultures of murine hematopoietic BMCs gave rise to spontaneous beating cell clusters in the presence of vascular endothelial and fibroblast growth factors. These clusters originated from c-kitpos cells. The formation of the clusters could be completely blocked by adding a c-kit/tyrosine kinase inhibitor, Gleevec (imatinib mesylate; Novartis International, Basel, Switzerland, http://www.novartis.com), to the culture. Cluster formation was also blunted in BMCs from c-kit-deficient (KitW/KitW-v) mice. Clustered cells expressed cardiomyocyte-specific transcription factor genes Gata-4 and Nkx2.5, sarcomeric proteins β-MHC and MLC-2v, and ANF and connexin-43. Immunostaining revealed α-sarcomeric actinin expression in more than 90% of clustered cells. Under electron microscopy, the clustered cells exhibited a sarcomeric myofiber arrangement and z-bands. This study defines the microenvironment required to achieve a reproducible in vitro model of beating, myogenic cell clusters. This model could be used to examine the mechanisms responsible for the postnatal myogenic differentiation of BMCs. Our results identify c-kitpos bone marrow hematopoietic cells as the source of the myogenic clusters. STEM CELLS 2009;27:1911–1920
29 citations
••
TL;DR: Parmacological chaperones that rescue mutant channel expression could have therapeutic potential to reduce the risk of LQTS2‐associated arrhythmias and sudden cardiac death, but only if the mutant Kv11.1 channels function normally after membrane expression is restored.
Abstract: Key points Most missense long QT syndrome type 2 (LQTS2) mutations result in Kv11.1 channels that show reduced levels of membrane expression. Pharmacological chaperones that rescue mutant channel expression could have therapeutic potential to reduce the risk of LQTS2-associated arrhythmias and sudden cardiac death, but only if the mutant Kv11.1 channels function normally (i.e. like WT channels) after membrane expression is restored. Fewer than half of mutant channels exhibit relatively normal function after rescue by low temperature. The remaining rescued missense mutant Kv11.1 channels have perturbed gating and/or ion selectivity characteristics. Co-expression of WT subunits with gating defective missense mutations ameliorates but does not eliminate the functional abnormalities observed for most mutant channels. For patients with mutations that affect gating in addition to expression, it may be necessary to use a combination therapy to restore both normal function and normal expression of the channel protein. Abstract In the heart, Kv11.1 channels pass the rapid delayed rectifier current (IKr ) which plays critical roles in repolarization of the cardiac action potential and in the suppression of arrhythmias caused by premature stimuli. Over 500 inherited mutations in Kv11.1 are known to cause long QT syndrome type 2 (LQTS2), a cardiac electrical disorder associated with an increased risk of life threatening arrhythmias. Most missense mutations in Kv11.1 reduce the amount of channel protein expressed at the membrane and, as a consequence, there has been considerable interest in developing pharmacological agents to rescue the expression of these channels. However, pharmacological chaperones will only have clinical utility if the mutant Kv11.1 channels function normally after membrane expression is restored. The aim of this study was to characterize the gating phenotype for a subset of LQTS2 mutations to assess what proportion of mutations may be suitable for rescue. As an initial screen we used reduced temperature to rescue expression defects of mutant channels expressed in Xenopus laevis oocytes. Over half (∼56%) of Kv11.1 mutants exhibited functional gating defects that either dramatically reduced the amount of current contributing to cardiac action potential repolarization and/or reduced the amount of protective current elicited in response to premature depolarizations. Our data demonstrate that if pharmacological rescue of protein expression defects is going to have clinical utility in the treatment of LQTS2 then it will be important to assess the gating phenotype of LQTS2 mutations before attempting rescue.
29 citations
••
TL;DR: Deletion of the gene encoding MMCP-4, markedly reduced late, but not early, infarct size by suppressing IGF-1 degradation and, consequently, diminished cardiac dysfunction and adverse structural remodeling is found.
Abstract: Heart disease is a leading cause of death in adults Here, we show that a few days after coronary artery ligation and reperfusion, the ischemia-injured heart elaborates the cardioprotective polypeptide, insulin-like growth factor-1 (IGF-1), which activates IGF-1 receptor prosurvival signaling and improves cardiac left ventricular systolic function However, this signaling is antagonized by the chymase, mouse mast cell protease 4 (MMCP-4), which degrades IGF-1 We found that deletion of the gene encoding MMCP-4 (Mcpt4), markedly reduced late, but not early, infarct size by suppressing IGF-1 degradation and, consequently, diminished cardiac dysfunction and adverse structural remodeling Our findings represent the first demonstration to our knowledge of tissue IGF-1 regulation through proteolytic degradation and suggest that chymase inhibition may be a viable therapeutic approach to enhance late cardioprotection in postischemic heart disease
29 citations
••
University of Queensland1, St. Vincent's Health System2, University of New South Wales3, Victor Chang Cardiac Research Institute4, Griffith University5, Florey Institute of Neuroscience and Mental Health6, QIMR Berghofer Medical Research Institute7, Royal Children's Hospital8, University of Melbourne9, University of Sydney10
TL;DR: In this paper, the role of acid sensing ion channel 1a (ASIC1a) in cardiac IRI at the cellular and whole organ level was investigated using genetic and pharmacological methods.
Abstract: Background: Ischemia-reperfusion injury (IRI) is one of the major risk factors implicated in morbidity and mortality associated with cardiovascular disease. During cardiac ischemia, the build-up of acidic metabolites results in decreased intracellular and extracellular pH that can reach as low as 6.0-6.5. The resulting tissue acidosis exacerbates ischemic injury and significantly impacts cardiac function. Methods: We used genetic and pharmacological methods to investigate the role of acid sensing ion channel 1a (ASIC1a) in cardiac IRI at the cellular and whole organ level. Human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) as well as ex vivo and in vivo models of IRI were used to test the efficacy of ASIC1a inhibitors as pre- and post-conditioning therapeutic agents. Results: Analysis of human complex trait genetics indicate that variants in the ASIC1 genetic locus are significantly associated with cardiac and cerebrovascular ischemic injuries. Using hiPSC-CMs in vitro and murine ex vivo heart models, we demonstrate that genetic ablation of ASIC1a improves cardiomyocyte viability after acute IRI. Therapeutic blockade of ASIC1a using specific and potent pharmacological inhibitors recapitulates this cardioprotective effect. We used an in vivo model of myocardial infarction (MI) and two models of ex vivo donor heart procurement and storage as clinical models to show that ASIC1a inhibition improves post-IRI cardiac viability. Use of ASIC1a inhibitors as pre- or post-conditioning agents provided equivalent cardioprotection to benchmark drugs, including the sodium-hydrogen exchange inhibitor zoniporide. At the cellular and whole organ level, we show that acute exposure to ASIC1a inhibitors has no impact on cardiac ion channels regulating baseline electromechanical coupling and physiological performance. Conclusions: Collectively, our data provide compelling evidence for a novel pharmacological strategy involving ASIC1a blockade as a cardioprotective therapy to improve the viability of hearts subjected to IRI.
29 citations
Authors
Showing all 728 results
Name | H-index | Papers | Citations |
---|---|---|---|
Bruce D. Walker | 155 | 779 | 86020 |
Stefanie Dimmeler | 147 | 574 | 81658 |
Matthias W. Hentze | 110 | 319 | 41879 |
Roland Stocker | 92 | 331 | 34364 |
Richard P. Harvey | 83 | 403 | 27060 |
Michael F. O'Rourke | 81 | 451 | 35355 |
Robert Terkeltaub | 80 | 284 | 21034 |
Robert M. Graham | 69 | 319 | 16342 |
Sunil Gupta | 69 | 440 | 33856 |
Anne Keogh | 64 | 337 | 20268 |
Filip K. Knop | 61 | 437 | 13614 |
Peter S. Macdonald | 57 | 455 | 12988 |
Boris Martinac | 56 | 245 | 14121 |
Carolyn L. Geczy | 55 | 187 | 8987 |
Christopher J. Ormandy | 54 | 131 | 8757 |